274 related articles for article (PubMed ID: 23210517)
1. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
3. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
[TBL] [Abstract][Full Text] [Related]
6. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
7. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
9. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
[TBL] [Abstract][Full Text] [Related]
10. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
[TBL] [Abstract][Full Text] [Related]
12. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
13. [Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
Agata M; Sameshima Y; Oda T; Kondo T; Ishiyama M; Yasunami T; Kazama H; Okamura T; Yoshinaga K; Shiseki M; Mori N; Yamada O; Sagawa K; Teramura M; Motoji T
Rinsho Ketsueki; 2010 Mar; 51(3):189-95. PubMed ID: 20379113
[TBL] [Abstract][Full Text] [Related]
14. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Bianchi G; Richardson PG; Anderson KC
J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
16. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
17. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
[TBL] [Abstract][Full Text] [Related]
18. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
19. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
20. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
